One Shot to Silence a Disease Forever

Lonvo-z takes a radically different approach. It uses lipid nanoparticles (tiny fat bubbles, similar to the ones in mRNA vaccines) to deliver CRISPR-Cas9 editing machinery directly to liver cells. Once inside, the system finds and cuts the KLKB1 gene, which is the blueprint for making kallikrein. The cell tries to repair the cut but introduces errors, permanently disabling the gene.

No more gene, no more kallikrein factory, no more runaway bradykinin. One infusion. Done.

The Durability Question Gets an Answer

Skeptics have always asked: sure, but how long does it last? Gene editing is permanent in theory, but biology is complicated.

Intellia's earlier Phase 1 follow-up data offers a compelling answer. Across all 10 patients in long-term follow-up, the therapy delivered a 98% mean reduction in monthly attacks, with every single patient remaining attack-free and treatment-free for a median of 23 months. Some patients have been attack-free for over 26 months and counting.

That's not a drug wearing off between doses. That's a rewritten genome holding steady for over two years.

The Competition Is Playing a Different Game

To appreciate what lonvo-z represents, consider what HAE patients deal with today. The standard-of-care options include lanadelumab (Takhzyro), a subcutaneous injection every two to four weeks; Haegarda, a C1 inhibitor replacement injected twice weekly; and berotralstat (Orladeyo), a daily oral pill. All are effective. All are expensive. And all require lifelong commitment.

Lonvo-z's secondary endpoints drove the point home further. Attacks requiring on-demand treatment dropped by 89%. Moderate-to-severe attacks fell by 91%. Quality of life scores improved by 17 points on a scale where 6 points is considered clinically meaningful.

These aren't incremental gains over existing therapies. They're a fundamentally different value proposition: one afternoon in an infusion chair versus a lifetime of needles and pills.

Wall Street Is Intrigued, Not Euphoric

You might expect a stock to rocket on data like this. The reality has been more complicated. Intellia shares popped about 23% on the detailed EAACI presentation, landing around $14.90.

The disconnect between promising data and a still-depressed stock comes down to two things. First, expectations were sky-high; "very good" data sometimes disappoints investors who priced in "miraculous." Second, Intellia's pipeline carries baggage. Serious liver toxicity events in the company's separate ATTR cardiomyopathy program knocked shares down over 40% in a single session earlier, creating an overhang that even blockbuster HAE data hasn't fully cleared.

Analyst sentiment is split but leans bullish. Leerink Partners reportedly raised its price target to around $35 and bumped the probability of lonvo-z's success to roughly 90%. Citizens valued the HAE program alone at about $21 per share. Meanwhile, Morgan Stanley holds an Equal Weight rating with a $15 target, flagging execution risk and commercial uncertainty.

Consensus targets cluster around the mid-$20s, well above the recent trading range, suggesting the Street thinks the science is real but the business case still needs proving.

Why This Matters Beyond HAE

Intellia is now on track for a rolling BLA submission (a staggered filing with the FDA) targeting a potential U.S. launch in the first half of 2027. If approved, lonvo-z would become the first systemic in vivo CRISPR therapy to reach the market.

That's a milestone for more than just HAE patients. It would validate the entire concept of one-time gene editing as a replacement for chronic disease management. The playbook could extend to Intellia's own ATTR amyloidosis program, to Verve Therapeutics' base-editing approach for familial high cholesterol, and eventually to dozens of liver-expressed genetic targets.

For HAE patients worldwide, the implications are personal. The best treatments available today ask them to plan their lives around injection schedules, pharmacy refills, and the ever-present anxiety of breakthrough attacks. Lonvo-z offers something those therapies never could: the possibility of walking away from all of it after a single visit.

The data isn't perfect. Long-term safety monitoring of permanent gene edits will need to continue for years. Payers will scrutinize the price tag of a one-time therapy versus annuities from chronic drugs. And the shadow of Intellia's safety issues in other programs won't vanish overnight.

But the core finding is hard to argue with. One infusion. Ninety-eight percent attack reduction sustained past two years. Most patients completely free of disease.

If that's not paradigm-shifting, the word has lost its meaning.

Adaptive Biotech Is Breaking Up With Itself

Adaptive Biotechnologies is splitting its profitable cancer diagnostics business from its early-stage drug discovery platform into two separate companies. The move follows a growing industry trend of corporate breakups designed to let fundamentally different businesses attract the right investors.